Long-term efficacy and safety of the interleukin-1 inhibitors anakinra and canakinumab in a patient with refractory Behçet's disease uveitis and concomitant bladder papillary carcinoma

Donato Rigante, Ida Orlando, Antonio Vitale, Giuseppe Lopalco, Claudia Fabiani, Luca Cantarini

Risultato della ricerca: Contributo in rivistaArticolo in rivista

6 Citazioni (Scopus)

Abstract

The authors describe a patient with Behçet's disease treated with anakinra and canakinumab after bladder papillary cancer excision. The same patient had been previously proven to be unresponsive to standard therapy, including TNF-α inhibitors.
Lingua originaleEnglish
pagine (da-a)1-5
Numero di pagine5
RivistaInternal Medicine Journal
Volume2017
DOI
Stato di pubblicazionePubblicato - 2017

Keywords

  • Behçet's disease

Fingerprint

Entra nei temi di ricerca di 'Long-term efficacy and safety of the interleukin-1 inhibitors anakinra and canakinumab in a patient with refractory Behçet's disease uveitis and concomitant bladder papillary carcinoma'. Insieme formano una fingerprint unica.

Cita questo